Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

LipimetiX Development

LipimetiX Development?uq=UG6efJS6
2012 FOUNDED
PRIVATE STATUS
Corporate LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer of drugs for cholesterol-related diseases. The company focuses on the development of drugs for the treatment of refractory hypercholesterolemia, hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company's technology is based upon a platform of chimeric peptide mimetics of apolipoprotein E, a critical protein that directs cholesterol and triglyceride-rich lipoproteins to receptors on the liver.

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
  • 5 Commonwealth Road
  • Suite 2A
  • Natick, MA 01760
  • United States

+1 (508) 000-0000

LipimetiX Development Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore LipimetiX Development‘s full profile, request access.

Request full access to PitchBook

LipimetiX Development Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore LipimetiX Development‘s full profile, request access.

Request full access to PitchBook

LipimetiX Development Executive Team (2)

Name Title Board
Seat
Contact
Info
Dennis Goldberg Ph.D President, Chairman & Co-Founder
Philip Friden Ph.D Vice President, Research & Development & Co-Founder